Lexeo Therapeutics Quote - LXEO

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

14.89

Bid

13.00

Ask

16.51

Volume

96,024

13.78 Day's Range 15.75

9.00 52 Week Range 22.33

Market Cap

490.556M

Previous Close

14.02

Open

13.78

Last Trade

15.2

Last Trade Time

Financial Volume

US$ 1,376,021

VWAP

14.33

Average Volume (3m)

161,569

Shares Outstanding

32,945,341

Dividend Yield

PE Ratio

-7.39

Earnings Per Share (EPS)

-2.02

Revenue

Net Profit

-66.39M

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t... Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.lexeotx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Lexeo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LXEO. The last closing price for Lexeo Therapeutics was US$14.02. Over the last year, Lexeo Therapeutics shares have traded in a share price range of US$ 9.00 to US$ 22.33.

Lexeo Therapeutics currently has 32,945,341 shares outstanding. The market capitalization of Lexeo Therapeutics is US$490.56 million. Lexeo Therapeutics has a price to earnings ratio (PE ratio) of -7.39.

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.73	-10.4091456077	16.62	17.36	13.65	236016	14.65139234	CS
4	-2.18	-12.7709431752	17.07	19.14	13.65	225400	16.69321211	CS
12	1.54	11.5355805243	13.35	19.14	11.57	161569	15.122935	CS
26	0.39	2.68965517241	14.5	22.33	11.57	130881	15.26584773	CS
52	5.39	56.7368421053	9.5	22.33	9	135250	14.44663459	CS
156	5.39	56.7368421053	9.5	22.33	9	135250	14.44663459	CS
260	5.39	56.7368421053	9.5	22.33	9	135250	14.44663459	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NCPNickel Creek Platinum Corp	$ 0.015 (50.00%)	222k
CJR.BCorus Entertainment Inc	$ 0.225 (28.57%)	2.79M
XLYAuxly Cannabis Group Inc	$ 0.03 (20.00%)	172.53k
AVCNAvicanna Inc	$ 0.405 (15.71%)	318.38k
EXNExcellon Resources Inc	$ 0.15 (15.38%)	32.87k
DNDelta 9 Cannabis Inc	$ 0.01 (-33.33%)	861.22k
IVQInvesque Inc	$ 0.15 (-16.67%)	6.5k
OPTOptiva Inc	$ 5.85 (-15.34%)	2.31k
DYADynaCERT Inc	$ 0.20 (-13.04%)	2.72M
BSXBelo Sun Mining Corp	$ 0.04 (-11.11%)	267.57k
TRPTC Energy Corporation	$ 52.13 (1.03%)	13.27M
TDToronto Dominion Bank	$ 76.02 (0.58%)	12.28M
FCUFission Uranium Corp	$ 1.24 (5.08%)	9.25M
CMCanadian Imperial Bank of Commerce	$ 66.18 (0.73%)	5.66M
BNSBank of Nova Scotia	$ 62.23 (-0.61%)	5.55M